Optimizerx Corp (OPRX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. OptimizeRx Corporation is a digital healthcare technology company connecting healthcare providers (HCPs) and patients through an omnichannel network. The company operates as a single reporting segment, focusing on enterprise-level engagements with life science organizations. As of July 25, 2025, there were 18,565,033 common shares outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $29.20 million | $18.81 million | $51.12 million | $38.50 million |
| Gross Profit | $18.64 million | $11.70 million | $31.98 million | $23.91 million |
| Gross Margin | 63.8% | 62.2% | 62.6% | 62.1% |
| Operating Income (Loss) | $3.19 million | ($3.75 million) | $1.08 million | ($8.78 million) |
| Net Income (Loss) | $1.53 million | ($4.01 million) | ($0.67 million) | ($10.91 million) |
| Diluted EPS | $0.08 | ($0.22) | ($0.04) | ($0.60) |
| Cash & Equivalents | $16.59 million (as of June 30, 2025) | |||
| Operating Cash Flow (YTD) | $8.43 million (2025) vs $2.90 million (2024) | |||
| Total Debt (Principal) | $29.29 million (Term Loan due 2027) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 55% year-over-year for Q2 and 33% for the six-month period, driven by growth in Direct-to-Consumer (DTC) and Dynamic Audience Activation Platform (DAAP) sales.
- Profitability Turnaround: The company returned to profitability in Q2 2025 with $1.53 million in net income, compared to a $4.01 million loss in Q2 2024. Operating income improved from a loss of $3.75 million to a profit of $3.19 million.
- Expense Management: Operating expenses remained flat for Q2 ($15.45 million) and decreased 5% YTD ($30.90 million vs $32.69 million). Stock-based compensation expense dropped significantly (down 49% YTD) due to lower grant fair values and the absence of prior CEO forfeiture costs.
- Debt Reduction: The company repaid $5.0 million in principal on its Term Loan during the first six months of 2025. The effective interest rate on the loan was 19.6% for Q2 2025, including amortization of issuance costs.
Outlook, Risks, and Unusual Items
- Guidance: The filing does not provide specific numerical guidance for the full year 2025. Management expects seasonality to continue, with the fourth quarter typically reflecting the highest activity levels.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a previously identified material weakness regarding the completeness and accuracy of data received from third-party service organizations. Remediation efforts are ongoing, including hiring a Senior Vice President of Internal Controls and implementing SOC-1 Type 2 audit requirements.
- Subsequent Events: On July 4, 2025, the "One Big Beautiful Bill Act" (OBBBA) was signed into law, extending tax provisions including 100% bonus depreciation. The company is currently assessing the financial impact.
- Risk Factors: Key risks include customer concentration (top 5 customers represented ~49% of 2024 revenue), dependence on channel partners, and the ability to service debt obligations. The company maintains a liquidity covenant requiring at least $5.0 million in liquidity, which it met as of June 30, 2025.
Investor Verification Checklist
- Remediation Progress: Verify the timeline and testing results for the remediation of the material weakness in internal controls over financial reporting.
- Debt Covenants: Confirm continued compliance with the Term Loan's leverage ratios and liquidity covenants, especially given the high effective interest rate (~19.6% in Q2).
- Customer Concentration: Monitor revenue reliance on the top 5 customers, which historically account for nearly half of total revenue.
- Seasonality Impact: Assess Q3 and Q4 performance to validate the expected seasonal revenue ramp-up typical in the pharmaceutical marketing industry.
- Tax Law Impact: Review future filings for the quantified impact of the OBBBA tax legislation signed in July 2025.